HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (44) Citing Articles via Google Scholar Google Scholar Articles by Gammaitoni, A. R. Articles by Galer, B. S. Search for Related Content PubMed PubMed Citation Articles by Gammaitoni, A. R. Articles by Galer, B. S. Social Bookmarking                         What's this?

Safety and Tolerability of the Lidocaine Patch 5%, a Targeted Peripheral Analgesic: A Review of the Literature

From Endo Pharmaceuticals, Chadds Ford, Pennsylvania

The safety, tolerability, and efficacy of the lidocaine patch 5% (Lidoderm®), a targeted peripheral analgesic with an FDA-approved indication for the treatment of postherpetic neuralgia, has been well established. Recent case reports and studies have suggested potential efficacy in other neuropathic and nonneuropathic pain conditions. Several pharmacokinetic studies have demonstrated minimal systemic absorption with 12-, 18-, and 24-hour/day dosing. Mean maximum plasma concentrations have shown the lidocaine patch to possess a minimal risk for systemic toxicities or drug-drug interactions. The most common adverse events generally involve mild skin reactions. There have been no drug-drug interactions noted in clinical trials. Recent evidence suggests that extended application does not result in A-ß-mediated sensory loss at the application site, which is particularly important in patients who already have a degree of sensory loss due to their underlying condition. The lidocaine patch provides a treatment option that carries a relatively low systemic adverse event and drug-drug interaction risk burden, even with continuous application of up to four patches per day.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. S. Habib, T. J. Polascik, A. Z. Weizer, W. D. White, J. W. Moul, M. A. ElGasim, and T. J. Gan Lidocaine Patch for Postoperative Analgesia After Radical Retropubic Prostatectomy Anesth. Analg., June 1, 2009; 108(6): 1950 - 1953. [Abstract] [Full Text] [PDF]

				K. E. Galluzzi Managing Neuropathic Pain J Am Osteopath Assoc, November 1, 2007; 107(suppl_6): ES39 - ES48. [Abstract] [Full Text] [PDF]

				J. Ko, A. Weil, L. Maxwell, T. Kitao, and T. Haydon Plasma Concentrations of Lidocaine in Dogs Following Lidocaine Patch Application J. Am. Anim. Hosp. Assoc., September 1, 2007; 43(5): 280 - 283. [Abstract] [Full Text] [PDF]

				I. W. Tremont-Lukats, V. Challapalli, E. D. McNicol, J. Lau, and D. B. Carr Systemic Administration of Local Anesthetics to Relieve Neuropathic Pain: A Systematic Review and Meta-Analysis Anesth. Analg., December 1, 2005; 101(6): 1738 - 1749. [Abstract] [Full Text] [PDF]

				P. F. White The Changing Role of Non-Opioid Analgesic Techniques in the Management of Postoperative Pain Anesth. Analg., November 1, 2005; 101(5S_Suppl): S5 - 22. [Abstract] [Full Text] [PDF]

				K. E. Galluzzi Management of Neuropathic Pain J Am Osteopath Assoc, September 1, 2005; 105(suppl_4): S12 - S19. [Abstract] [Full Text] [PDF]

				V. L. Ghafoor Treatment of Chronic Pain Journal of Pharmacy Practice, August 1, 2003; 16(4): 249 - 260. [Abstract] [PDF]

				V. L. Ghafoor Management of Painful Conditions in the Elderly Journal of Pharmacy Practice, August 1, 2003; 16(4): 276 - 283. [Abstract] [PDF]